Pfizer clinical trials portal stresses privacy

Share this article:

Pfizer is launching an “online community” designed to speed clinical trials recruitment while safeguarding patient privacy rights.

Pfizer is collaborating with software developer Private Access on the portal. The firm's proprietary technology lets patients control to whom and for what purposes they grant access to their personal health info, so that they can, for example, allow only researchers focused on the conditions that interest them access.

The company cited an Institute of Medicine study that found that the number one reason patients who were aware of trials were not willing to participate was fear that their health info would not remain confidential.

“Many patients who could benefit from participation in clinical trials don't enroll in them because they are not aware that potentially relevant research is underway or they cannot find a specific trial to meet their needs,” said Pfizer chief medical officer Freda Lewis-Hall, MD. “Others worry that they will lose control of their health information.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...